SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IGT ((VSE:IGT) Blockbuster Anti-Cancer Test Results !!!
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Solid Play who wrote ()4/27/1998 8:12:00 PM
From: jean paul sauvT  Read Replies (1) of 94
 
Pre-clinical studies for Anhydrovinblastine progressing

IGT Pharma Inc IGT
Shares issued 8,190,914 Apr 27 close $0.90
Mon 27 Apr 98 News Release
Mr. Bruce Schmidt reports
Pre-clinical studies are progressing at the British Columbia Cancer Agency
in Vancouver and Roswell Park Cancer Institute in Buffalo.
The studies being conducted were developed with the primary objective of
obtaining preclinical and toxicology data of Anhydrovinblastine to file an
investigational new drug submission to the Health Protection Branch in
order to begin a phase I clinical studies in cancer patients to begin later
this summer. The pertinent studies have been completed and the preliminary
indications are positive and continue to support the investigational new
drug submission of Anhydrovinblastine.
The Medical Oncology Department at the British Columbia Cancer Agency will
be conducting the phase I clinical trial at the clinical site in Vancouver
later this summer. The clinical investigation team has been appointed
consisting of three clinical oncologists and one medical oncology
investigator. The phase I study clinical protocol outline has been written
and is pending approval from the BC Cancer Agency's internal review board.
The clinical supplies for the trials are being manufactured and will
undergo formulation into the final injectable dosage form. Upon subsequent
release of the clinical batch, the required drug supply will ready for the
phase I study.
The contract research organizations involved with the studies have
completed or are in the final stages of analyzing and auditing data. The
final reports for most of the studies have been assembled by the company's
regulatory team and are awaiting submission pending receipt of the final
reports from the last group of animals from the studies. This toxicology
report is now scheduled for completion Jul. 1, 1998, shortly after, which
the investigational new drug submission will be filed.
(c) Copyright 1998 Canjex Publishing Ltd. canada-stockwatch.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News